All posts by imreal

Researchers Focus on New Strain of Hydrilla Found Thriving in the Connecticut River


News Image

Greg Bugbee, a scientist with the Connecticut Agricultural Experiment Station, says the new invader has begun to replace the native eelgrass that provides a critical habitat for fish, mussels and other aquatic life. It has also begun to clog tributaries and coves along the river.

Hydrilla is well-known for invading lakes, ponds and waterways, especially across the southeastern U.S. But experts with the Weed Science Society of America (WSSA) say a new strain of the weed has now been found along a 70-mile portion of the 400-mile-long Connecticut River.

Hydrilla is the most widespread of the 19 aquatic weeds on the federal noxious weed list. It also represents a significant ecological and economic risk. That’s especially true for the environmentally rich Connecticut River, which begins on the Canadian border, spans four states and empties into the Long Island Sound.

The river has a major impact on the region and its economy. It supports fish, birds and other wildlife; farms, fisheries, marinas and other businesses; and the recreation and water needs of millions of residents who live and work nearby.

First discovered in 2016, the new hydrilla strain is spreading quickly. Recent surveys show the infestation has produced dense mats of floating hydrilla biomass that now cover nearly 1,000 acres of the river. And the impact is already being felt.

Greg Bugbee, a scientist with the Connecticut Agricultural Experiment Station, says the new invader has begun to replace the native eelgrass that provides a critical habitat for fish, mussels and other aquatic life. It has also begun to clog tributaries and coves along the river – making them impassible to motorboats used for touring, fishing and other water sports. The hydrilla engulfs propellor blades and causes engines to stall – a problem researchers faced firsthand as they conducted their survey of the river.

Bugbee says the new strain is genetically distinct from hydrilla found elsewhere, with differences in how it grows and reproduces. It is hardy and tolerates a wide range of growing conditions. Unlike other hydrilla strains in the U.S., it has yet to be observed producing potato-like tubers that can be buried in the sediment of rivers, lakes and ponds.

That may offer a control advantage, Bugbee says, since tubers can be hard to locate and remove and can sprout after remaining dormant for many years. By comparison, the new strain seems to spread primarily through axillary and basal turions – budlike nodules on the plant’s stem that can break off and root where they drop.

There are still lots of unknowns, though. Scientists don’t yet know how this genotype is best controlled. They also don’t know whether it can harbor neurotoxin-producing algae that can kill eagles, ospreys and coots – something that occurs among the warm-weather hydrilla found in the southeastern U.S. There is also great concern that this strain of hydrilla could be spread to other bodies of water by boats, canoes, kayaks and other sports equipment that can transport small fragments of the weed to new locations.

Fortunately, work is actively underway by various stakeholders to fill the information gap. One of the many agencies engaged in that effort is the U.S. Army Corps of Engineers, particularly at their Engineer Research and Development Center in Vicksburg, Mississippi. Michael Greer, the Corps’ program manager for aquatic nuisance species research, says his team is working closely with local, state and regional groups and is spearheading several initiatives that are already underway or on the horizon:

  •      It has funded a nationwide effort to expand what we know about the genetics of hydrilla – identifying the various strains of the invader, determining their range and measuring the extent of their infestation.
  •      It has funded research to explore the biology of the new Connecticut River variant and to conduct lab studies to determine how the nuisance species responds to the herbicides registered for control of aquatic weeds.
  •      It is working with partners from across the region to plan a Connecticut River field study that will serve as a proof of concept in how best to control the new genotype and restore the important ecological and economic benefits of the river.

“In effect, we’re writing a ‘book of knowledge’ that will capture the life history of this new strain, how it spreads and how to manage it effectively,” Greer says. “We hope to bring what we learn from our research into a real world setting and build a body of best management practices.”

To Learn More

  •      Explore a map of the Connecticut River Basin.
  •      Watch a video describing the hydrilla invasion on the Connecticut River.
  •      Read the Connecticut Agricultural Experiment Station’s report on hydrilla and other aquatic plants on the Connecticut River.
  •      Explore the five-year hydrilla management plan for the Connecticut River developed in 2020 by the Northeast Aquatic Nuisance Species Panel.
  •      Visit the Connecticut River Conservancy to find out more about hydrilla and the steps each of us can take to help slow its spread.

About the Weed Science Society of America

The Weed Science Society of America, a nonprofit scientific society, was founded in 1956 to encourage and promote the development of knowledge concerning weeds and their impact on the environment. The Society promotes research, education and extension outreach activities related to weeds, provides science-based information to the public and policy makers, fosters awareness of weeds and their impact on managed and natural ecosystems, and promotes cooperation among weed science organizations across the nation and around the world. For more information, visit http://www.wssa.net. The Aquatic Plant Management Society (APMS) is a national affiliate of WSSA.

EDITORS: Photos to support this press release can be downloaded from the WSSA website at https://wssa.net/credit-lines-for-hydrilla-photos.

Share article on social media or email:

Flow Control Holdings Names New Chief Executive Officer


“I look forward to working closely with the team at Audax to execute against the compelling opportunity in front us and leverage the resources Audax brings to the table to pursue a buy and build strategy that we expect to accelerate growth in the future.”Scott Kerns, CEO

Flow Control Holdings (“FCH”), a leading provider of sanitary flow components to producers of foods, beverages and pharmaceuticals, announced today the appointment of Scott Kerns to the position of Chief Executive Officer.

Kerns succeeds Phil Pejovich, who has served as CEO since 2018 and will stay on with the company in an advisory capacity as a member of the company’s board of directors.

“We are delighted to welcome Scott to the FCH team and are confident that his experience will benefit the company as it accelerates its growth in the coming years. I look forward to supporting him in my new role as a member of the board,” commented Phil Pejovich.

Ryan Bruehlmann, Managing Director at Audax, added, “We are thrilled to gain a high-caliber executive with a strong track record of driving growth and accelerating strategic execution. Scott will be instrumental in guiding Flow Control Holdings as the company continues its pursuit of an aggressive growth path.”

Scott has an extensive commercial and operational experience and was most recently the CEO of private equity-backed Control Devices, LLC, where he led significant enhancement and expansion of the company and oversaw its recent sale to HBM Holdings in October 2021. He also guided the company on its subsequent integration into the HBM Holdings portfolio.

Prior to that, Scott served as a senior executive with the IDEX Corporation, where he held two Divisional President positions in the Health & Science Technologies Group. Scott also spent 22 years at Arconic (FKA: Alcoa). There, he served in multiple roles, including: Vice President in Hungary; General Manager of the Alcoa Commercial Vehicle Wheels business for Europe, South Africa and Japan; and as Vice President of Global Affairs and Business Development in the United States.

Scott holds an MBA from the Fuqua School of Business, Duke University, and a bachelor’s degree from University of North Carolina at Greensboro.

“Flow Control Holdings has a sterling reputation across its distribution network and among systems integrators, and the company’s successful track record is a testament to the team, Phil’s leadership, and the relationships the company has formed across its end markets,” commented Scott Kerns. “I look forward to working closely with the team at Audax to execute against the compelling opportunity in front us and leverage the resources Audax brings to the table to pursue a buy and build strategy that we expect to accelerate growth in the future.”

Don Bramley, Managing Director at Audax Private Equity, added, “On behalf of everyone at Audax Private Equity, we want to thank Phil for all that he has done for FCH, and we look forward to his continued support as he transitions to the board of directors.”

ABOUT FLOW CONTROL HOLDINGS:

Founded in 2018, Flow Control Holdings specializes in providing highly engineered sanitary and high purity flow components for market-critical applications within the food, beverage, and pharmaceutical industries. For more information, visit the FCH website, at http://www.flowcontrolholdings.com.

ABOUT AUDAX PRIVATE EQUITY

Audax Group is a leading alternative investment manager with offices in Boston, New York, San Francisco and London. Since its founding in 1999, the firm has raised over $32 billion in capital across its Private Equity and Private Debt businesses. Audax Private Equity has invested over $9 billion in more than 150 platforms and over 1,100 add-on companies, and is currently investing in add-ons out of its $3.5 billion, sixth private equity fund. Through its disciplined Buy & Build approach, Audax seeks to help platform companies execute add-on acquisitions that fuel revenue growth, optimize operations, and significantly increase equity value. With more than 360 employees and over 150 investment professionals, the firm is a leading capital partner for North American middle market companies. For more information, visit the Audax Private Equity website, at http://www.audaxprivateequity.com, or follow us on LinkedIn. ​​​​​​​

For more information, please contact:

Audax Private Equity

Julie Rudnick

FGS Global

audax@fgsglobal.com

Share article on social media or email:

Red Nucleus (“RN”) Expands Medical Communications Business Unit, Acquires AlphaGroup Medical Communications, LLC (“AlphaGroup” or the “Company”)


RN, a premier provider of strategic learning and development, scientific services and advisory, medical communications solutions, and market access and commercialization services exclusively for the life sciences industry, announced that it has acquired AlphaGroup, renowned for delivering leading scientific, medical affairs, and outcomes communication services for the pharmaceutical, biotech, and medical device/diagnostic industries. The Company’s services are high science, with over half its employees possessing advanced scientific degrees. AlphaGroup has expansive therapeutic expertise in oncology, virology, transplantation, immunology, rare diseases, gene therapy, and cardiology.

AlphaGroup, founded in 2005 by Stephen Douthwaite, provides a focused set of scientific and medical communications solutions centered on key medical activities throughout a product’s life cycle, beginning in pre-clinical development and spanning through FDA approval, product launch, and continued marketing efforts. The Company brings expertise in the areas of scientific medical communications (including manuscript, abstract, and poster development and strategic publication planning), medical affairs communications (including MSL tools, interactive educational and training tools, slide decks, publications, and KOL engagement), and health economics and outcomes research (HEOR), real world evidence (RWE), and payer communications. AlphaGroup brings new clients and extended services to the combined business.

Mike Smith, AlphaGroup Group Managing Director, said “Our commitment to delivering the highest quality communication services in the industry remains our top priority and was at the forefront of our decision to join Red Nucleus. Their industry reputation, global scale, and infrastructure to support our ongoing rapid growth made this a natural fit for our team and for our clients.”

“We are excited to be joining an organization that shares our core values of precision, integrity, and passion, and we look forward to collaborating closely with the rest of the medical communications business unit within RN to bring extended capabilities to our clients,” AlphaGroup Chief Strategy Officer Ed Shifflett adds.

“As internal and external collaboration grows across the pharmaceutical industry, winning agency partners will demonstrate true integration and a world class customer experience. AlphaGroup extends our Medical Communications capabilities across publications and medical affairs and brings exciting new services within the HEOR and RWE space,” adds Philip McCrea, Global President, Medical Communications at Red Nucleus.

“We are elated AlphaGroup has joined the Red Nucleus family as we continue our relentless drive to bring differentiated value to our clients across the product life cycle as we execute on our strategy of providing capability coverage from molecule to market,” said Red Nucleus CEO Ian Kelly.

The transaction closed in December 2022.

For more information, please contact

Media Contact:

Kelly Curtin

kcurtin@rednucleus.com

(917) 880-3449

About Red Nucleus

We are a global strategic partner with decades of experience across the entire life sciences product life cycle. We excel in providing our clients unique insights and efficiencies to support their journey to improve health outcomes and ultimately the quality of people’s lives. Our “red thread” weaves together a full suite of products and services from advisory, scientific, market access, medical communications, and learning and development that leads our life sciences clients to accelerated transformational success.

Share article on social media or email:

This Holiday Season it is Essential to Gift Responsibly to Children


Gambling addiction is a concern across all populations and is a growing problem among youth. Therefore, it is up to all of us to be attentive to the gifts we select for children.

The Florida Council on Compulsive Gambling (FCCG), in partnership with the National Council on Problem Gambling, is urging parents and adults to take the time necessary to determine what gifts might be best for children this holiday season. “The Gift Responsibly campaign, during National Safe Toys and Gifts Awareness Month in December is an opportunity for adults to be reminded that certain games and forms of entertainment, such as lottery tickets and scratch offs, are not harmless activities,” explained Jennifer Kruse, Executive Director of the FCCG. Research findings show a direct relationship with receiving lottery tickets and scratch offs during childhood with risky, problematic gambling later in life [1]. “Gambling addiction is a concern across all populations and is a growing problem among youth. Therefore, it is up to all of us to be attentive to the gifts we select for children,” Kruse added.

Each year, parents and others find themselves uncertain of what gifts might be best for a child or teenager. In many cases, shoppers opt for gift cards because they allow recipients the freedom to purchase what they want. Others may choose to buy video games, while some may place lottery tickets or scratch offs in a holiday card or stocking stuffer. However, while adults may believe these options appear harmless, it is essential to keep the following in mind:


  • Gift cards work well when parents and adults monitor how they are used.
  • Some video games contain gambling like features, so it’s essential to research the item prior to purchasing.
  • Lottery games are never appropriate for minors and equally important, youth are unaware of the associated risks of gambling.

At times minors are gaining access to gambling because parents and other unknowing adults are providing entry. Further, despite the legal gambling age of 18, Florida prevalence research revealed 18.5% of adolescents ages 13-17 reported purchasing lottery tickets in their lifetime and 12.5% within the past year [2]. In addition, the study found [3]:

  • Lifetime participation rates for gambling neared 70%.
  • Over 40% reported gambling in the past year and 11.5% identified as weekly gamblers.
  • Adolescent problem gamblers also had much higher rates of alcohol, drug, and tobacco use.

Exacerbating matters is Florida schools still do not educate children about gambling addiction, limiting instruction to alcohol and substance abuse. “Therefore, as parents and loved ones, we need to educate our children about the consequences of gambling. We also need to spend more time on gifting responsibly because it matters. It’s also imperative that we identify creative ideas for presents that encourage time spent with loved ones and do not break our budgets or our holiday spirit this season,” concluded Kruse.

Finally, if you are concerned about your own, a child or another loved one’s gambling, help is available 24/7. One contact to Your One Sure Thing, 888-ADMIT-IT, is confidential and multilingual, and can secure the assistance needed. The Problem Gambling HelpLine may be reached by phone (888-ADMIT-IT), text (321-978–0555), live chat (gamblinghelp.org), email (fccg@gamblinghelp.org) or on social media, such as Facebook and Twitter.

The Florida Council on Compulsive Gambling, Inc. (FCCG) is a not-for-profit corporation under contract with Florida State government, serving as the designated state affiliate of the National Council on Problem Gambling (NCPG). In addition to operating the 24-hour Problem Gambling HelpLine (888-ADMIT-IT), the FCCG increases awareness of problem gambling through education and outreach efforts throughout the state of Florida, advocates on behalf of the public regarding issues relating to problem gambling, and provides programs, resources, and other population specific supports to those in need of assistance.

1. National Council on Problem Gambling. “Gift Responsibly Campaign”, https://www.ncpgambling.org/programs-resources/gift-responsibly-campaign/.

2. Shapira, N. A., Ferguson, M. A., Frost-Pineda, K., & Gold, M. S. (2002). Gambling and Problem Gambling Prevalence among Adolescents in Florida.

3. Ibid.

Share article on social media or email:

Icosagen Chooses Genedata Biologics to Digitalize Recombinant Antibody Discovery


News Image

“Since many of the biopharma and biotechs we work with as a CRDMO also use Genedata, it makes it even easier to exchange data with our customers,” said Mart Ustav Jr., Ph.D., Chief Scientific Officer of Icosagen.

Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Icosagen, a research-driven organization providing services for the discovery and production of mammalian cell-derived biopharmaceuticals, has deployed Genedata Biologics® to digitalize and automate their recombinant antibodies discovery services in Europe and the U.S.

“We were looking for a solution with out-of-the-box functionality tailored for large molecule R&D and chose Genedata Biologics because it has everything we need to digitalize our antibody discovery and protein manufacturing operations,” said Mart Ustav Jr., Ph.D., Chief Scientific Officer of Icosagen. “Since many of the biopharma and biotechs we work with as a CRDMO also use Genedata, it makes it even easier to exchange data with our customers. We are also very pleased with Genedata’s support and global presence, which gives us local access to support our operations both in Europe and the U.S.”

Icosagen Cell Factory has custom-tailored services from discovery, hit-to-lead finding, pre-clinical candidate selection, up to early-stage clinical candidate development to provide recombinant antibodies and proteins to the biopharmaceutical and biotechnology industry. Genedata Biologics is used to automate and digitalize the full end-to-end discovery process at Icosagen, streamlining library generation, phage display selection and B-Cell screening, cloning and expression, IgG reformatting, lead characterization and developability assessment, candidate selection, and manufacturing along with cell line development.

“When I first met Genedata scientists at a conference, I was impressed with their deep level of understanding of antibody discovery processes, and their suggestions on how Icosagen could increase throughput and improve R&D operational efficiency,” said Joan Teyra, Ph.D., Principal Scientist at Icosagen. “This expertise was confirmed during deployment and roll-out of the Genedata platform. Genedata is helping us to get up and running with spot-on suggestions on how to best streamline our processes and improve data quality.”

“We are excited that Icosagen, a distinguished CRDMO, has chosen Genedata Biologics to digitalize their antibody operations,” said Othmar Pfannes, Ph.D., CEO of Genedata. “Since Genedata Biologics is purpose-built for biotherapeutics and the platform of choice among top biopharma and biotech companies, more and more CRDMOs are adopting our platform to streamline operations and more easily share information with their biopharma customers.”

About Icosagen CRDMO

Icosagen is a research-driven contract research, development and manufacturing organization for biopharmaceutical, and biotechnology industries, focused on the production of functional recombinant proteins and antibody discovery. Icosagen’s unique CRDMO concept allows seamless transitions from transient R&D milligrams into stable high-producing cell lines and GMP manufacturing in several hundred-liter scale. Project and molecule know-how therefore stays in one single facility with one team and under one legal framework.

http://www.icosagen.com

About Genedata

Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.

http://www.genedata.com

LinkedIn | Twitter | YouTube

________________________________________

Contact

Allison Kurz

Genedata

Public Relations

pr@genedata.com

Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company’s products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Share article on social media or email:



BLR’s EHS Hero Expands its Fleet of Digital Workplace Safety Modules with New Industrial Hygiene Tool


“Adding this workflow solution to guide you through your sampling program and allowing common documentation and automated follow up on findings provides another tool to further simplify EHS leaders’ tasks and reporting.”—Kevin Shoemaker, BLR Solutions Engineer

EHS Hero®, BLR’s leading safety management & compliance platform, continues to grow its best-in-class fleet of built-for-action tools with the addition of an Industrial Hygiene Module. This tool supports a company’s EHS team with lab analysis and sampling, chain-of-custody documentation, equipment management, and action management all in one unified, integrated solution. This tool is available within what is already the most advanced and comprehensive EHS management solution currently available.

This latest addition combines intuitive sampling data storage and instrument tracking with automatic creation of action plans, allowing users to spend less time on data entry and reporting while reducing risk and avoiding OSHA penalties regarding total maximum daily load (TMDL) or permissible exposure limit (PEL) violations.

The EHS Hero team recognized that EHS professionals spend a significant amount of time managing industrial hygiene documents, which can make creating actionable plans based on sampling results more difficult. This new EHS Hero solution will allow those professionals to search and find sampling results within seconds so they can perform rapid analysis and make informed decisions.

“The Industrial Hygiene solution is a much-needed addition to our core tools. It follows our simple to use and useful values,” says Solutions Engineer Kevin Shoemaker. “Adding this workflow solution to guide you through your sampling program and allowing common documentation and automated follow up on findings provides another tool to further simplify EHS leaders’ tasks and reporting.”

For more information on the new EHS Hero solution, visit https://ehshero.blr.com/industrial-hygiene.

About Simplify Compliance

For over 40 years, Simplify Compliance has provided the nation’s top businesses with the latest knowledge and regulatory information to make decisive, positive, and productive decisions in a continuously evolving business environment. Serving a range of industries, including health care, human capital management, and telecommunications, Simplify Compliance provides timesaving products and solutions that help businesses monitor compliance, implement best practices, and optimize financial performance to achieve their goals. Simplify Compliance proudly operates BLR®, M. Lee Smith, CCMI, HCPro, DecisionHealth, HealthLeaders, and Bluepoint. For more information, visit http://www.simplifycompliance.com.

About BLR

Business and Learning Resources (BLR), a division of Simplify Compliance LLC, is an industry-leading knowledge provider in the human capital management; environment, health, and safety; learning and development; and legal markets. With over 43 years of experience, BLR provides publications, workflow platforms, and tools; over 600 eLearning courses; instructor-led training; and additional solutions to achieve compliance and maximize efficiencies, resulting in measurable performance and financial improvements. That’s why the nation’s top companies and over 30,000 businesses rely on BLR for the most comprehensive and reliable state-specific and federal legal guidance and education and learning opportunities to respond quickly in today’s continuously evolving business environment. Visit https://www.blr.com/.

Share article on social media or email:

Craig Foster Joins Wisdo Health as Chief Revenue Officer


“We are thrilled that Craig Foster is joining our team to further establish our role as the leader in peer support while tackling the loneliness epidemic,” stated Boaz Gaon, Founder and CEO of Wisdo Health.

Wisdo Health, the award-winning social health platform for peer support and clinical referrals has proudly announced the appointment of Craig Foster as Chief Revenue Officer.

Craig brings over 20 years of experience with digital health and virtual care solutions and will assume a leading role in spearheading Wisdo Health’s growth in the U.S. market among health plans and employers.

“We are thrilled that Craig is joining our team to further establish our role as the leader in peer support while tackling the loneliness epidemic,” stated Boaz Gaon, Founder and CEO of Wisdo Health. “Having validated our impact with health insurance leaders and employers to improve health and drastically reduce cost, Craig is uniquely poised to help Wisdo change Social Health in America.”

Craig has successfully supported four startup companies to IPO, including Radiant Systems, Lawson Software, i2 Technologies, and Castlight Health, and has previously worked with Vivante Health as Senior Vice President of Commercial and at Vida Health as Senior Vice President of Sales.

Craig Foster commented: “I’m joining at a pivotal point in Wisdo Health’s growth in the market and I’m looking forward to working with the team. Wisdo Health’s platform has the potential to profoundly impact loneliness at scale, affecting over 60% of America’s adult population, and I’m very proud to work for such an important cause.”

About Wisdo Health:

Wisdo Health is an evidence-based peer support and clinical referral platform designed to address the harmful consequences of loneliness, social isolation, and lack of engagement on health outcomes and costs. Wisdo Health uses a data-driven model to map users’ life challenges, goals, and obstacles to health, then proactively connects them with helpful peers who have been in their shoes. Through Wisdo Health, members enjoy emotional support, weekly group coaching to build social skills, and referrals to clinical and SDOH solutions offered to users through their employer and health plans. To date, over 500,000 adults have joined Wisdo Health. Learn more at http://www.wisdo.com

Media Contact:

Debra Emanuel

Head of Marketing

debra@wisdo.com

Share article on social media or email: